GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was £7.93B, up 97.3% from the year before. Over ten years it grew -2.6% a year on average. The highest annual figure on record is £10.32B in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £7.93B | +97.3% |
| FY2024 | Dec 31, 2024 | £4.02B | -40.4% |
| FY2023 | Dec 31, 2023 | £6.75B | +4.8% |
| FY2022 | Dec 31, 2022 | £6.43B | +47.6% |
| FY2021 | Dec 31, 2021 | £4.36B | -27.1% |
| FY2020 | Dec 31, 2020 | £5.98B | -14.1% |
| FY2019 | Dec 31, 2019 | £6.96B | +27.0% |
| FY2018 | Dec 31, 2018 | £5.48B | +34.2% |
| FY2017 | Dec 31, 2017 | £4.09B | +57.3% |
| FY2016 | Dec 31, 2016 | £2.60B | -74.8% |
| FY2015 | Dec 31, 2015 | £10.32B | – |